Science
When Covid-19 hit, Gilead Sciences Inc. had enough of its experimental drug remdesivir ready to test and start manufacturing it at a larger scale. That's because it had started stockpiling not just the drug, but its ingredients, at the first hint there may be a new coronavirus. Robert Langreth reports on why the company was able to act early to prepare for a pandemic when so many businesses and institutions did not.
See omnystudio.com/listener for privacy information.
More Episodes
Biden’s Pandemic Response Overhaul
2020-12-02
2020-12-02
A Bubble Made Up of Millions
2020-11-30
2020-11-30
Business, Interrupted
2020-11-27
2020-11-27
Where to Be in a Pandemic
2020-11-25
2020-11-25
Governors Brace For Winter
2020-11-23
2020-11-23
Can Enclosed Outdoor Dining Really Be Safe?
2020-11-20
2020-11-20
Can We Make Enough Covid Drugs?
2020-11-18
2020-11-18
Dr. Fauci on What the Vaccine News Means
2020-11-16
2020-11-16
A Global Virus Report Card
2020-11-13
2020-11-13
Special Edition: The Next Year of the Virus
2020-11-11
2020-11-11
The Cost of Taking Cases to Zero
2020-11-09
2020-11-09
One College Is Containing Covid
2020-11-06
2020-11-06
Your Questions About the Coming Winter
2020-11-04
2020-11-04
Inside the Push For a Vaccine in the U.S.
2020-11-02
2020-11-02
Fighting the Misinformation Crisis
2020-10-30
2020-10-30
The Obsession With a Vaccine Could Hurt Us
2020-10-28
2020-10-28
The Dangers of Pollution in a Pandemic
2020-10-23
2020-10-23
What Herd Immunity Really Means
2020-10-21
2020-10-21
Europe's Coronavirus Déjà Vu
2020-10-19
2020-10-19
Get this podcast on your
phone, FREE
